Skip to main content

Advertisement

SpringerLink
Log in

The potential prognostic utility of salivary galectin-3 concentrations in heart failure

  • Original Paper
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

A Correction to this article was published on 10 December 2019

This article has been updated

Abstract

Background

Patients with HF are at a higher risk of rehospitalisation and, as such, significant costs to our healthcare system. A non-invasive method to collect body fluids and measure Gal-3 could improve the current management of HF. In this study, we investigated the potential prognostic utility of salivary Galectin-3 (Gal-3) in patients with heart failure (HF).

Methods

We collected saliva samples from patients with HF (n = 105) either at hospital discharge or during routine clinical visits. Gal-3 concentrations in saliva samples were measured by ELISA. The Kaplan–Meier survival curve analysis and Cox proportional regression model were used to determine the potential prognostic utility of salivary Gal-3 concentrations.

Results

The primary end point was either cardiovascular death or hospitalisation. Salivary Gal-3 concentrations were significantly higher (p < 0.05) in patients with HF who subsequently experienced the primary endpoint compared to those who did not. HF patients with salivary Gal-3 concentrations > 172.58 ng/mL had a significantly (p < 0.05) higher cumulative risk of the primary endpoint compared to those with lower salivary Gal-3 concentrations. In patients with HF, salivary Gal-3 concentration was a predictor of the primary endpoint even after adjusting for other covariates.

Conclusions

In our pilot study, HF patients with salivary Gal-3 concentrations of > 172.58 ng/mL demonstrated a higher cumulative risk of the primary outcome compared to those with lower Gal-3 levels, even after adjusting for other variables. Confirming our findings in a larger multi-centre clinical trial in the future would enable salivary Gal-3 measurements to form part of routine management for patients with HF.

Graphical abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Change history

  • 10 December 2019

    The original version of this article unfortunately contained a mistake.

References

  1. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, Nodari S, Lam CSP, Sato N, Shah AN, Gheorghiade M (2014) The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 63(12):1123–1133. https://doi.org/10.1016/j.jacc.2013.11.053

    Article  PubMed  Google Scholar 

  2. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, Murabito JM, Vasan RS, Benjamin EJ, Levy D, Framingham Heart S (2002) Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106(24):3068–3072. https://doi.org/10.1161/01.cir.0000039105.49749.6f

    Article  PubMed  Google Scholar 

  3. Krumholz HM, Merrill AR, Schone EM, Schreiner GC, Chen J, Bradley EH, Wang Y, Wang Y, Lin Z, Straube BM, Rapp MT, Normand SL, Drye EE (2009) Patterns of hospital performance in acute myocardial infarction and heart failure 30-day mortality and readmission. Circ Cardiovasc Qual Outcomes 2(5):407–413. https://doi.org/10.1161/CIRCOUTCOMES.109.883256

    Article  PubMed  Google Scholar 

  4. de Boer RA et al (2009) Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 11(9):811–817. https://doi.org/10.1093/eurjhf/hfp097

    Article  CAS  PubMed  Google Scholar 

  5. Henderson NC et al (2009) The regulation of inflammation by galectin-3. Immunol Rev 230(1):160–171. https://doi.org/10.1111/j.1600-065X.2009.00794.x

    Article  CAS  PubMed  Google Scholar 

  6. McCullough PA, Olobatoke A, Vanhecke TE (2011) Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Rev Cardiovasc Med 12(4):200–210. https://doi.org/10.3909/ricm0624

    Article  PubMed  Google Scholar 

  7. Suthahar N, Meijers WC, Silljé HHW, Ho JE, Liu F-T, de Boer RA (2018) Galectin-3 activation and inhibition in heart failure and cardiovascular disease: an update. Theranostics 8(3):593–609. https://doi.org/10.7150/thno.22196

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Christenson RH, Duh SH, Wu AH, Smith A, Abel G, deFilippi CR, Wang S, Adourian A, Adiletto C, Gardiner P (2010) Multi-center determination of galectin-3 assay performance characteristics: anatomy of a novel assay for use in heart failure. Clin Biochem 43(7–8):683–690. https://doi.org/10.1016/j.clinbiochem.2010.02.001

    Article  CAS  PubMed  Google Scholar 

  9. de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, van Veldhuisen DJ (2011) Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 43(1):60–68. https://doi.org/10.3109/07853890.2010.538080

    Article  CAS  PubMed  Google Scholar 

  10. Schindler EI, Szymanski JJ, Hock KG, Geltman EM, Scott MG (2016) Short- and long-term biologic variability of galectin-3 and other cardiac biomarkers in patients with stable heart failure and healthy adults. Clin Chem 62(2):360–366. https://doi.org/10.1373/clinchem.2015.246553

    Article  CAS  PubMed  Google Scholar 

  11. US Food and Drug Administration (2010) 510(k) Substantial equivalence determination decision summary. Review Memorandum K093758

  12. US Food and Drug Administration (2014) 510(k) Substantial equivalence determination decision summary. Review Memorandum K140436

  13. Pfaffe T, Cooper-White J, Beyerlein P, Kostner K, Punyadeera C (2011) Diagnostic potential of saliva: current state and future applications. Clin Chem 57(5):675–687. https://doi.org/10.1373/clinchem.2010.153767

    Article  CAS  PubMed  Google Scholar 

  14. Topkas E, Keith P, Dimeski G, Cooper-White J, Punyadeera C (2012) Evaluation of saliva collection devices for the analysis of proteins. Clin Chim Acta 413(13–14):1066–1070. https://doi.org/10.1016/j.cca.2012.02.020

    Article  CAS  PubMed  Google Scholar 

  15. Mohamed R, Campbell JL, Cooper-White J, Dimeski G, Punyadeera C (2012) The impact of saliva collection and processing methods on CRP, IgE, and Myoglobin immunoassays. Clin Transl Med 1(1):19. https://doi.org/10.1186/2001-1326-1-19

    Article  PubMed  PubMed Central  Google Scholar 

  16. Punyadeera C, Dimeski G, Kostner K, Beyerlein P, Cooper-White J (2011) One-step homogeneous C-reactive protein assay for saliva. J Immunol Methods 373(1–2):19–25. https://doi.org/10.1016/j.jim.2011.07.013

    Article  CAS  PubMed  Google Scholar 

  17. Esser D, Alvarez-Llamas G, de Vries MP, Weening D, Vonk RJ, Roelofsen H (2008) Sample stability and protein composition of saliva: implications for its use as a diagnostic fluid. Biomarker Insights 3:25–27

    Article  CAS  Google Scholar 

  18. Zhang X, Wan Y, Chata R, Brazzale A, Atherton JJ, Kostner K, Dimeski G, Punyadeera C (2016) A pilot study to demonstrate diagnostic potential of galectin-3 levels in saliva. J Clin Pathol 69(12):1100–1104. https://doi.org/10.1136/jclinpath-2016-203631

    Article  CAS  PubMed  Google Scholar 

  19. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects (2013). JAMA 310 (20):2191–2194. https://doi.org/10.1001/jama.2013.281053

  20. Australian Research Council and Universities Australia (2018) Australian code for responsible conduct of research. R41 edn. National Health and Medical Research Council

  21. Atherton JJ, Sindone A, De Pasquale CG, Driscoll A, MacDonald PS, Hopper I, Kistler PM, Briffa T, Wong J, Abhayaratna W, Thomas L, Audehm R, Newton P, O'Loughlin J, Branagan M, Connell C (2018) National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018. Heart Lung Circ 27(10):1123–1208. https://doi.org/10.1016/j.hlc.2018.06.1042

    Article  PubMed  Google Scholar 

  22. Dolgin M, Committee NYHAC, (1994) Nomenclature and criteria for diagnosis of diseases of the Heart and Great Vessels, vol 567. Little, Brown and Company, Boston

    Google Scholar 

  23. Navazesh M (1993) Methods for collecting saliva. Ann N Y Acad Sci 694:72–77. https://doi.org/10.1111/j.1749-6632.1993.tb18343.x

    Article  CAS  PubMed  Google Scholar 

  24. Zhang X, Walsh T, Atherton JJ, Kostner K, Schulz B, Punyadeera CK (2017) Identification and validation of a salivary protein panel to detect heart failure early. Theranostics 7(18):4350–4358. https://doi.org/10.7150/thno.21727

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. van der Merwe L, Wan Y, Cheong HJ, Perry C, Punyadeera C (2018) A pilot study to profile salivary angiogenic factors to detect head and neck cancers. BMC Cancer 18(1):734. https://doi.org/10.1186/s12885-018-4656-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Wan YX, Vagenas D, Salazar C, Kenny L, Perry C, Calvopina D, Punyadeera C (2017) Salivary miRNA panel to detect HPV-positive and HPV-negative head and neck cancer patients. Oncotarget 8(59):99990–100001. https://doi.org/10.18632/oncotarget.21725

    Article  PubMed  PubMed Central  Google Scholar 

  27. Rifai N, Gillette MA, Carr SA (2006) Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 24(8):971–983. https://doi.org/10.1038/nbt1235

    Article  CAS  PubMed  Google Scholar 

  28. Sittampalam GS, Coussens NP, Brimacombe K, Grossman A, Arkin M, Auld D, Austin C, Baell J, Bejcek B, Caaveiro JMM, Chung TDY, Dahlin JL, Devanaryan V, Foley TL, Glicksman M, Hall MD, Haas JV, Inglese J, Iversen PW, Kahl SD, Kales SC, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Trask OJ, Jr., Weidner JR, Wildey MJ, Xia M, Xu X (2004). In: Assay guidance manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda (MD),

  29. Hara M, Ono K, Hwang MW, Iwasaki A, Okada M, Nakatani K, Sasayama S, Matsumori A (2002) Evidence for a role of mast cells in the evolution to congestive heart failure. J Exp Med 195(3):375–381. https://doi.org/10.1084/jem.20002036

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. MacKinnon AC, Farnworth SL, Hodkinson PS, Henderson NC, Atkinson KM, Leffler H, Nilsson UJ, Haslett C, Forbes SJ, Sethi T (2008) Regulation of alternative macrophage activation by galectin-3. J Immunol 180(4):2650–2658. https://doi.org/10.4049/jimmunol.180.4.2650

    Article  CAS  PubMed  Google Scholar 

  31. Frunza O, Russo I, Saxena A, Shinde AV, Humeres C, Hanif W, Rai V, Su Y, Frangogiannis NG (2016) Myocardial galectin-3 expression is associated with remodeling of the pressure-overloaded heart and may delay the hypertrophic response without affecting survival, dysfunction, and cardiac fibrosis. Am J Pathol 186(5):1114–1127. https://doi.org/10.1016/j.ajpath.2015.12.017

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Nguyen M-N, Su Y, Vizi D, Fang L, Ellims AH, Zhao W-B, Kiriazis H, Gao X-M, Sadoshima J, Taylor AJ, McMullen JR, Dart AM, Kaye DM, Du X-J (2018) Mechanisms responsible for increased circulating levels of galectin-3 in cardiomyopathy and heart failure. Sci Rep 8(1):8213. https://doi.org/10.1038/s41598-018-26115-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Lok DJ, Klip IT, Lok SI, Bruggink-Andre de la Porte PW, Badings E, van Wijngaarden J, Voors AA, de Boer RA, van Veldhuisen DJ, van der Meer P (2013) Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure. Am J Cardiol 112(6):831–837. https://doi.org/10.1016/j.amjcard.2013.05.013

    Article  CAS  PubMed  Google Scholar 

  34. Zhang Y, Zhang R, An T, Huang Y, Guo X, Yin S, Wang Y, Ji S, Lv R, Zhang J, Maisel A (2015) The utility of galectin-3 for predicting cause-specific death in hospitalized patients with heart failure. J Card Fail 21(1):51–59. https://doi.org/10.1016/j.cardfail.2014.10.006

    Article  CAS  PubMed  Google Scholar 

  35. Koukoui F, Desmoulin F, Galinier M, Barutaut M, Caubère C, Evaristi MF, Murat G, De Boer R, Berry M, Smih F, Rouet P (2015) The prognostic value of plasma galectin-3 in chronic heart failure patients is maintained when treated with mineralocorticoid receptor antagonists. PLoS ONE 10(3):e0119160–e0119160. https://doi.org/10.1371/journal.pone.0119160

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL, van Veldhuisen DJ (2010) Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 99(5):323–328. https://doi.org/10.1007/s00392-010-0125-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Clark RA, Driscoll A, Nottage J, McLennan S, Coombe DM, Bamford EJ, Wilkinson D, Stewart S (2007) Inequitable provision of optimal services for patients with chronic heart failure: a national geo-mapping study. Med J Aust 186(4):169–173. https://doi.org/10.5694/j.1326-5377.2007.tb00855.x

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The cost of sample collection, reagent for experiment and wages was supported by the National Heart Foundation of Australia Vanguard grant. XZ was awarded a QUT PhD write-up scholarship to write this article. We would like to thank the clinical staff at the Royal Brisbane and Women's Hospital, the Prince Charles Hospital and the Mater Hospital for assisting with clinical samples and data collection.

Funding

Funding has been received from Queensland University of Technology Grand Number 100966.

Author information

Authors and Affiliations

  1. Saliva and Liquid Biopsy Translational Research Team, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, 60 Musk Avenue, GPO Box 2434, Brisbane, QLD, 4001, Australia

    Xi Zhang, Nuwan Karunathilaka & Chamindie Punyadeera

  2. Australian Centre For Health Services Innovation, Queensland University of Technology, Brisbane, QLD, Australia

    Sameera Senanayake

  3. School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD, Australia

    V. Nathan Subramaniam

  4. Critical Care Research Group, The Prince Charles Hospital, Brisbane, QLD, Australia

    Wandy Chan & John Fraser

  5. Department of Cardiology, Mater Adult Hospital, Brisbane, QLD, Australia

    Karam Kostner

  6. Cardiology Department, Royal Brisbane and Women’s Hospital and University of Queensland School of Medicine, Brisbane, QLD, Australia

    John J. Atherton

Authors
  1. Xi Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nuwan Karunathilaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sameera Senanayake
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V. Nathan Subramaniam
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wandy Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Karam Kostner
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. John Fraser
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. John J. Atherton
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Chamindie Punyadeera
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chamindie Punyadeera.

Ethics declarations

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (XLSX 34 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, X., Karunathilaka, N., Senanayake, S. et al. The potential prognostic utility of salivary galectin-3 concentrations in heart failure. Clin Res Cardiol 109, 685–692 (2020). https://doi.org/10.1007/s00392-019-01557-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-019-01557-0

Keywords

Search

Navigation